Log in

KYNB Kyntra Bio, Inc. NASDAQ · United States

Kyntra Bio (KYNB) news KYNB delisting, offering, Nasdaq notice and merger news

Latest Kyntra Bio news

  1. Debt Financing

    Kyntra Bio cuts royalty financing cap to $65 million

    Kyntra Bio amended its royalty financing agreement with NQ Project Phoebus, L.P., lowering the maximum payments and making a $42.6 million upfront payment.

  2. Legal

    Kyntra Bio accrues $7.0 million for indemnity tied to SEC case against ex-CMO

    Kyntra Bio, formerly FibroGen, says it must advance legal costs for an SEC case against its former chief medical officer and may have to cover some costs and judgments. It had accrued about $7.0 million for those obligations at June 30, 2026, up from an amount it called not material three months earlier.

  3. Listings

    Kyntra Bio gets Nasdaq deficiency notice on $50 million total assets and revenue rule

    The April 2, 2026 letter cites Listing Rule 5450(b)(3)(A) and revenue of FibroGen International held for sale. Kyntra Bio has 45 days, until May 18, 2026, to submit a plan to regain compliance.

  4. Mergers

    FibroGen (now Kyntra Bio) completes $220 million China unit sale to AstraZeneca

    FibroGen used part of the proceeds to repay about $81 million of Morgan Stanley Tactical Value term loans. Pro forma total equity turns positive only with minority interests counted, while the stockholders' deficit attributable to FibroGen remains.

  5. Mergers

    FibroGen (now Kyntra Bio) extends Fortis merger option deadline to December 31, 2027

    FibroGen, now Kyntra Bio, and Fortis Therapeutics amended their evaluation agreement and option and merger agreement, moving the option exercise deadline.

  6. Listings

    FibroGen (now Kyntra Bio) appeals Nasdaq delisting notice after missing minimum bid price deadline

    FibroGen did not regain compliance by March 11, 2025 and appealed a Nasdaq delisting decision on March 14, 2025. The delisting is stayed pending a Hearings Panel ruling.

  7. Financings

    FibroGen (now Kyntra Bio) sets up $30.0 million at-the-market stock program

    BofA Securities will sell shares as agent for a commission of up to 3.0%. The stock last sold at $0.7724 before the filing.

Kyntra Bio annual financials

LineFY2025FY2024
Revenue$6.4 million$29.6 million
Research and development$23.5 million$95.7 million
Net income (loss)$183.5 million-$47.6 million
Cash from operations-$4.8 million-$138.0 million
Cash and equivalents$47.9 million$50.5 million
Short-term investments$41.1 million$0

Latest balance sheet, Jun 30, 2026 (10-Q): cash and equivalents $50.6 million, plus short-term investments of $40.7 million, $91.3 million in all.

Figures as reported to the SEC in XBRL; each one links to its filing. Not adjusted, not investment advice.

Questions about Kyntra Bio

Was Kyntra Bio delisted?

Our latest story on this, dated Oct 6, 2026: "Kyntra Bio gets Nasdaq delisting determination, requests a hearing". The story links the filing or release it is based on. Read the story.

Has Kyntra Bio raised money recently?

Our latest story on this, dated Feb 24, 2025: "FibroGen (now Kyntra Bio) sets up $30.0 million at-the-market stock program". The story links the filing or release it is based on. Read the story.

Has Kyntra Bio received a Nasdaq deficiency notice?

Our latest story on this, dated Apr 9, 2026: "Kyntra Bio gets Nasdaq deficiency notice on $50 million total assets and revenue rule". The story links the filing or release it is based on. Read the story.

Is Kyntra Bio involved in a merger or acquisition?

Our latest story on this, dated Mar 28, 2025: "FibroGen (now Kyntra Bio) extends Fortis merger option deadline to December 31, 2027". The story links the filing or release it is based on. Read the story.

What is the ticker symbol of Kyntra Bio?

Kyntra Bio, Inc. trades under the ticker KYNB on NASDAQ.

Where is Kyntra Bio listed?

Kyntra Bio, Inc. is listed on NASDAQ. Our directory also records these other listings: LS:A419WK; LSE:0IL8; LSX:A419WK.

What is the SEC CIK of Kyntra Bio?

The SEC Central Index Key (CIK) for Kyntra Bio, Inc. is 921299. Its filings are on SEC EDGAR.

How many shares does Kyntra Bio have outstanding?

4,049,124 shares as of 2026-07-31, per the cover page of its 10-Q filed 2026-08-13.

Which country or territory is Kyntra Bio listed under?

Our directory records Kyntra Bio, Inc. under United States.

What does Kyntra Bio do?

Our directory classifies Kyntra Bio, Inc. as: Pharmaceuticals: Major. This is a directory classification, not a description of the pipeline.

What is the ISIN of Kyntra Bio?

The ISIN recorded for Kyntra Bio, Inc. is US31572Q8814.

Does aibio.space cover Kyntra Bio?

aibio.space lists Kyntra Bio, Inc. among 2,820 public biotech companies and publishes its news here as stories appear.

What was Kyntra Bio's revenue last year?

$6.4 million for the fiscal year ended Dec 31, 2025, as reported to the SEC.

Is Kyntra Bio profitable?

Kyntra Bio, Inc. reported net income of $183.5 million for the fiscal year ended Dec 31, 2025, and used $4.8 million of cash in operations, per its annual report to the SEC.

How much does Kyntra Bio spend on research and development?

$23.5 million in the fiscal year ended Dec 31, 2025, per its annual report.

Investor discussion: Kyntra Bio

Members talk about Kyntra Bio (KYNB). Reader posts, not aibio.space reporting, and not investment advice.

Rules
  1. Securities violations are strictly forbidden. No market manipulation, no pump-and-dump, no false or misleading statements, and no inside information.
  2. Say whether you hold the stock. Every post states long, short or no position.
  3. No paid or sponsored posts. Do not post for anyone who pays or rewards you.
  4. No buy or sell calls and no price targets.
  5. No accusations of crime or fraud against named people unless you link a court filing or a regulator's release that makes them.
  6. No personal details and no spam. No links at all for your first 7 days as a member.

Posts that break the rules may be deleted without notice, and the account restricted or closed. See the terms and the privacy policy.

Capital-markets timeline

Financings, listing notices, splits, legal actions and other investor events at Kyntra Bio, newest first. Each line links the filing it comes from.

  1. Listings

    Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). Source

  2. Listings

    Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 3.01). Source

  3. Financings

    Reported a financing. SEC Form 8-K (Items 5.03,8.01,9.01). Source

  4. Mergers

    Reported completing an acquisition or a sale of assets. SEC Form 8-K (Items 2.01,9.01). Source

  5. Distress

    Reported the end of a material agreement. SEC Form 8-K (Items 1.02). Source

  6. Listings

    Reported a reverse stock split. SEC Form 8-K (Items 3.03,5.03,9.01). Source

  7. Listings

    Reported a shareholder vote on a reverse stock split or more authorized shares. SEC Form 8-K (Items 1.01,5.02,5.07,9.01). Source

  8. Listings

    Asked shareholders to approve a reverse stock split. SEC Form DEF 14A. Source

  9. Listings

    Asked shareholders to approve a reverse stock split. SEC Form PRE 14A. Source

  10. Mergers

    Reported a merger or acquisition agreement. SEC Form 8-K (Items 1.01). Source

  11. Listings

    Reported a notice from its stock exchange about continued listing requirements. SEC Form 8-K (Items 2.02,3.01,9.01). Source

  12. Financings

    Reported a financing. SEC Form 424B5. Source

  13. Distress

    Reported substantial doubt about its ability to continue as a going concern. SEC Form 10-Q. Source

Stock chart

Price chart and quote supplied by TradingView, delayed as the exchange requires. It loads only if you choose to show it. Information only, not investment advice. Open NASDAQ:KYNB on TradingView.

SEC filings and registration

SEC name
Kyntra Bio, Inc.
CIK
921299
Industry (SIC)
Pharmaceutical Preparations (2834)
US tickers
KYNB (Nasdaq)
Fiscal year ends
December 31
Filer category
Non-accelerated filer<br>Smaller reporting company
Business address
350 BAY STREET, SAN FRANCISCO, CA, 94133
Phone
415-978-1200
Shares outstanding
4,049,124 as of 2026-07-31 (10-Q filed 2026-08-13)
Former names
FIBROGEN INC

Recent filings (8-K and 6-K are the company's own announcements)

  • 8-K filed 2026-10-06
  • 8-K filed 2026-10-01
  • 8-K filed 2026-08-31
  • 10-Q filed 2026-08-13
  • 8-K filed 2026-08-13
  • 8-K filed 2026-06-16
  • 8-K filed 2026-06-09
  • 10-Q filed 2026-05-12

Source: SEC EDGAR, retrieved October 23, 2026. Shares outstanding is the cover-page figure from the latest periodic report. The SEC does not publish share prices.

Listing details

Kyntra Bio, Inc. is a public biotech or pharmaceutical company listed on NASDAQ under the ticker KYNB, recorded under United States. The directory classifies it as Pharmaceuticals: Major. aibio.space tracks 2,820 public biotech companies worldwide and publishes investor news on them.

Company
Kyntra Bio, Inc.
Ticker
KYNB
Listing
NASDAQ
Country or territory
United States
Business scope
Pharmaceuticals: Major
ISIN
US31572Q8814
Other listed symbols
LS:A419WK; LSE:0IL8; LSX:A419WK
Last quote in directory
2026-10-21
Directory source
Listing page

Listing facts come from our company directory, researched on October 22, 2026. A listing record does not certify that a security currently trades. Tell us about a change. Work at this company? Claim this page.

Published and maintained by aibio.space. Not investment advice. How we work.

Who manages this page This page is managed by aibio.space. The company does not run, edit or pay for this page. News, desk views and Investor Ranks are written and managed independently by aibio.space under our editorial and analytical judgment. Opinion only, not investment advice. How we work · Terms · Request a correction

aibio.space

Full desks

Every other company has a starter desk. Search above to open one.

Settings

Appearance
Text size
Motion

Stops the news strip and the share rollers.

Your choices are saved in this browser only.

Free membership

Read aibio.space in full, free

Subscribe with your email address to read every story, company desk and profile in full. It costs nothing. In return, you agree that we may email you, including offers. One click to unsubscribe.

No card, no password. With email, we send one message to confirm your address first. With Google or Facebook we receive only your email address. Not investment advice.